At the 14th biennial conference of the Huntington’s Disease Foundation (HDF), a record crowd of some 300 researchers from around the globe pushed the frontiers of science in their urgent quest for treatments for this devastating, deadly brain disorder.
Held August 10-13 at the Royal Sonesta Hotel in Cambridge, MA, the event was called HD2026: 14th Milton Wexler Biennial Symposium, in honor of the founder of the HDF, which until 2025 was known as the Hereditary Disease Foundation.
From genome editing to artificial intelligence (AI) as a research tool, from HD as a developmental advantage to clinical trial programs, HD2026 explored the hottest topics in Huntington’s science. The symposium took place in the spirit of the HDF’s emphasis on collaboration and group brainstorming, including a two-day genome-editing workshop beforehand for specialists. Participants included academics, biopharma reps, advocates like me, and leaders of other HD organizations.
Click here to read my report on HD2026.
